

Mylab transforms new-born screening with breakthrough point-of-care solution

28 September 2023 | News

Newborn screening is a critical public health program involving the testing of newborn infants for specific genetic, metabolic, and congenital disorders shortly after birth

Pune-based startup Mylab Discovery Solutions has announced a ground-breaking advancement in new-born screening (NBS) with the introduction of its patent-pending Point-of-Care device named MyNeoShield for new-born screening.

This device is set to transform the landscape of new-born healthcare by making screening faster, more accessible, and more affordable, ultimately saving lives and preventing lifelong illnesses. The device supports all the seven tests done for new-born screening globally- G-6-Phosphate Dehydrogenase Deficiency (G-6-PDD); Galactosemia; Phenylketonuria; Biotinidase Deficiency; 17-Hydroxyprogesterone; Immunoreactive Trypsinogen; and thyroid stimulating hormone (TSH).

Traditionally, new-born screening has been a complex process, involving the collection of samples from new-borns, their transportation to centralised testing centres, and a wait time of up to a day or more for results. This time-consuming process posed significant logistical challenges, especially in remote or underserved areas because the doctors only have a window of 48 hours to take any action. Additionally, the high cost of specialised equipment made it difficult for smaller healthcare facilities, like nursing homes, to offer these critical tests.

This innovative device brings the power of new-born screening directly to healthcare providers, allowing for quick and efficient testing at the point of care.

This Point-of-Care device for newborn screening is set to be available commercially from November. The company plans to take the device to global markets with its partners.